General Coverage Requirements
Coverage for eligible medical treatments, procedures, drugs, devices, or biological products is provided only when ALL of the following are met:
ALL of the following
Benefits are available in the member's contract or certificate.
Medical necessity criteria and guidelines are met.
Initial Therapy — Crohn's Disease
Covered when ALL of the following criteria are met:
ALL of the following
Patient is 18 years of age or older.
Patient has moderately to severely active Crohn's disease.
Patient has failed treatment with conventional therapies such as corticosteroids, 6-mercaptopurine (6-MP), and azathioprine, unless clinical evidence or patient history suggests these products will be ineffective or cause an adverse reaction.
The requested drug is NOT used in combination with other biologic disease-modifying antirheumatic drugs (DMARDs), such as adalimumab (Humira, biosimilars) or etanercept (Enbrel), or other drugs such as apremilast (Otezla) or tofacitinib (Xeljanz/XR).
Patient has a negative tuberculosis (TB) test, such as a purified protein derivative (PPD) or blood test, before treatment.
The requested dose is no higher than 400 mg initially and at weeks 2 and 4, followed by 400 mg every four weeks.
Continuation Therapy — Crohn's Disease
Covered when ALL of the following criteria are met:
ALL of the following
Patient has received an initial authorization for Cimzia from the plan OR has provided documentation of authorization for an active course of treatment from a previous health plan.
Patient has experienced a beneficial clinical response from baseline before Cimzia, evidenced by improvement in objective measures such as fecal or serum inflammatory markers, endoscopic findings, or reduced corticosteroid use, or in symptoms such as pain, fatigue, stool frequency, or blood in stool.
The requested dose is no higher than 400 mg initially and at weeks 2 and 4, followed by 400 mg every four weeks.
The requested drug is NOT used in combination with other biologic DMARDs, such as adalimumab (Humira, biosimilars) or etanercept (Enbrel), or other drugs such as apremilast (Otezla) or tofacitinib (Xeljanz/XR).
Initial Therapy — Rheumatoid Arthritis
Covered when ALL of the following criteria are met:
ALL of the following
Patient is 18 years of age or older.
Patient has moderately to severely active rheumatoid arthritis.
Patient has failed treatment with one or more traditional DMARDs, such as methotrexate, unless clinical evidence or patient history suggests these products will be ineffective or cause an adverse reaction.
Cimzia is NOT used in combination with other biologic DMARDs, such as adalimumab (Humira, biosimilars) or etanercept (Enbrel), or other drugs such as apremilast (Otezla) or tofacitinib (Xeljanz/XR).
Patient has a negative TB test, such as a PPD or blood test, before treatment.
Continuation Therapy — Rheumatoid Arthritis
Covered when ALL of the following criteria are met:
ALL of the following
Patient has received an initial authorization for Cimzia from the plan OR has provided documentation of authorization for an active course of treatment from a previous health plan.
Patient has experienced a beneficial clinical response from baseline before Cimzia, evidenced by decreased joint pain, morning stiffness, or fatigue; improved function or activities of daily living; or decreased soft tissue swelling in joints or tendon sheaths.
The requested dose is no higher than 400 mg initially and at weeks 2 and 4, followed by 200 mg every other week; a maintenance dose of 400 mg every 4 weeks can also be considered.
Cimzia is NOT used in combination with other biologic DMARDs, such as adalimumab (Humira, biosimilars) or etanercept (Enbrel), or other drugs such as apremilast (Otezla) or tofacitinib (Xeljanz/XR).
Initial Therapy — Psoriatic Arthritis
Covered when ALL of the following criteria are met:
ALL of the following
Patient is 18 years of age or older.
Patient has active psoriatic arthritis.
Patient has failed treatment with one or more traditional DMARDs, such as methotrexate, unless clinical evidence or patient history suggests these products will be ineffective or cause an adverse reaction.
Cimzia is NOT used in combination with other biologic DMARDs, such as adalimumab (Humira, biosimilars) or etanercept (Enbrel), or other drugs such as apremilast (Otezla) or tofacitinib (Xeljanz/XR).
Patient has a negative TB test, such as a PPD or blood test, before treatment.
Continuation Therapy — Psoriatic Arthritis
Covered when ALL of the following criteria are met:
ALL of the following
Patient has received an initial authorization for Cimzia from the plan OR has provided documentation of authorization for an active course of treatment from a previous health plan.
Patient has experienced a beneficial clinical response from baseline before Cimzia, evidenced by decreased joint pain, morning stiffness, or fatigue; improved function or activities of daily living; or decreased soft tissue swelling in joints or tendon sheaths.
The requested dose is no higher than 400 mg initially and at weeks 2 and 4, followed by 200 mg every other week; a maintenance dose of 400 mg every 4 weeks can also be considered.
Cimzia is NOT used in combination with other biologic DMARDs, such as adalimumab (Humira, biosimilars) or etanercept (Enbrel), or other drugs such as apremilast (Otezla) or tofacitinib (Xeljanz/XR).
Initial Therapy — Ankylosing Spondylitis
Covered when ALL of the following criteria are met:
ALL of the following
Patient is 18 years of age or older.
Patient has active ankylosing spondylitis.
Patient has failed treatment with nonsteroidal anti-inflammatory drugs (NSAIDs), unless clinical evidence or patient history suggests these products will be ineffective or cause an adverse reaction.
Cimzia is NOT used in combination with other biologic DMARDs, such as adalimumab (Humira, biosimilars) or etanercept (Enbrel), or other drugs such as apremilast (Otezla) or tofacitinib (Xeljanz/XR).
Patient has a negative TB test, such as a PPD or blood test, before treatment.
Continuation Therapy — Ankylosing Spondylitis
Covered when ALL of the following criteria are met:
ALL of the following
Patient has received an initial authorization for Cimzia from the plan OR has provided documentation of authorization for an active course of treatment from a previous health plan.
Patient has experienced a beneficial clinical response from baseline before Cimzia, evidenced by improvement in objective measures such as ASDAS, BASDAI, or inflammatory serum markers, or by reduced pain, stiffness, or improved daily functioning.
The requested dose is no higher than 400 mg initially and at weeks 2 and 4, followed by 200 mg every 2 weeks or 400 mg every 4 weeks.
Cimzia is NOT used in combination with other biologic DMARDs, such as adalimumab (Humira, biosimilars) or etanercept (Enbrel), or other drugs such as apremilast (Otezla) or tofacitinib (Xeljanz/XR).
Initial Therapy — Plaque Psoriasis
Covered when ALL of the following criteria are met:
ALL of the following
Patient is 18 years of age or older.
Patient has moderate to severe plaque psoriasis.
Patient is a candidate for phototherapy or systemic therapy.
Cimzia is NOT used in combination with other biologic DMARDs, such as adalimumab (Humira, biosimilars) or etanercept (Enbrel), or other drugs such as apremilast (Otezla) or tofacitinib (Xeljanz/XR).
Patient has a negative TB test, such as a PPD or blood test, before treatment.
Continuation Therapy — Plaque Psoriasis
Covered when ALL of the following criteria are met:
ALL of the following
Patient has received an initial authorization for Cimzia from the plan OR has provided documentation of authorization for an active course of treatment from a previous health plan.
Patient has experienced a beneficial clinical response from baseline before Cimzia, evidenced by reduced estimated body surface area affected by psoriasis, decreased erythema, induration/thickness, or scaling, and/or improvement in pain, itching, or burning.
The requested dose is no higher than 400 mg every other week.
Cimzia is NOT used in combination with other biologic DMARDs, such as adalimumab (Humira, biosimilars) or etanercept (Enbrel), or other drugs such as apremilast (Otezla) or tofacitinib (Xeljanz/XR).
Initial Therapy — Non-radiographic Axial Spondyloarthritis
Covered when ALL of the following criteria are met:
ALL of the following
Patient has active non-radiographic axial spondyloarthritis confirmed by the presence of sacroiliitis on magnetic resonance imaging (MRI).
Patient has failed at least TWO months of current continuous therapy with at least TWO different oral NSAIDs at prescription-strength dosages, unless clinical evidence or patient history suggests these products will be ineffective or cause an adverse reaction.
Patient is 18 years of age or older.
Cimzia is NOT used in combination with other biologic DMARDs, such as adalimumab (Humira, biosimilars) or etanercept (Enbrel), or other drugs such as apremilast (Otezla) or tofacitinib (Xeljanz/XR).
Patient has a negative TB test, such as a PPD or blood test, before treatment.
Continuation Therapy — Non-radiographic Axial Spondyloarthritis
Covered when ALL of the following criteria are met:
ALL of the following
Patient has received an initial authorization for Cimzia from the plan OR has provided documentation of authorization for an active course of treatment from a previous health plan.
Patient has experienced a beneficial clinical response from baseline before Cimzia, evidenced by improvement in objective measures such as ASDAS, BASDAI, or inflammatory serum markers, or by reduced pain, stiffness, or improved daily functioning.
The requested dose is no higher than 400 mg initially and at weeks 2 and 4, followed by 200 mg every 2 weeks or 400 mg every 4 weeks.
Cimzia is NOT used in combination with other biologic DMARDs, such as adalimumab (Humira, biosimilars) or etanercept (Enbrel), or other drugs such as apremilast (Otezla) or tofacitinib (Xeljanz/XR).
Initial Therapy — Polyarticular Juvenile Idiopathic Arthritis
Covered when ALL of the following criteria are met:
ALL of the following
Patient has a diagnosis of active polyarticular juvenile idiopathic arthritis.
Patient has failed treatment with one or more traditional DMARDs, such as methotrexate, unless clinical evidence or patient history suggests these products will be ineffective or cause an adverse reaction.
Cimzia is NOT used in combination with other biologic DMARDs, such as adalimumab (Humira, biosimilars) or etanercept (Enbrel), or other drugs such as apremilast (Otezla) or tofacitinib (Xeljanz/XR).
Patient has a negative TB test, such as a PPD or blood test, before treatment.
Initial Therapy — Polyarticular Juvenile Idiopathic Arthritis: Applicable Dosing Options
The patient must meet ONE of the following weight-based dosing options:
ONE of the following
For patients weighing 10 kg to less than 20 kg, the requested dose is no higher than 100 mg at weeks 0, 2, and 4, followed by 50 mg every 2 weeks.
For patients weighing 20 kg to less than 40 kg, the requested dose is no higher than 200 mg at weeks 0, 2, and 4, followed by 100 mg every 2 weeks.
For patients weighing greater than or equal to 40 kg, the requested dose is no higher than 400 mg at weeks 0, 2, and 4, followed by 200 mg every 2 weeks.
Continuation Therapy — Polyarticular Juvenile Idiopathic Arthritis
Continuation coverage requires the applicable criteria below:
ALL of the following
Patient has received an initial authorization for Cimzia from the plan OR has provided documentation of authorization for an active course of treatment from a previous health plan.
Patient has experienced a beneficial clinical response from baseline before Cimzia, evidenced by improved range of motion, reduced joint pain or tenderness, decreased duration of morning stiffness or fatigue, improved function or activities of daily living, reduced corticosteroid dosage, or improvement in inflammatory serum markers.
ONE of the following weight-based dosing options
For patients weighing 10 kg to less than 20 kg, the requested dose is no higher than 100 mg at weeks 0, 2, and 4, followed by 50 mg every 2 weeks.
For patients weighing 20 kg to less than 40 kg, the requested dose is no higher than 200 mg at weeks 0, 2, and 4, followed by 100 mg every 2 weeks.
Authorization, if granted, is for the lyophilized single-dose vial only. It does not apply to the non-lyophilized prefilled syringe. If authorization is granted, it applies only to the medical benefit.
Cimzia must not be used in combination with other biologic DMARDs, such as adalimumab (Humira, biosimilars) or etanercept (Enbrel), or with apremilast (Otezla) or tofacitinib (Xeljanz/XR), where prohibited by the applicable indication criteria.
Blue Advantage does not cover investigational or experimental services, including any drug, device, procedure, or service provided under the investigational arm of a clinical trial or study, unless mandated by the Centers for Medicare and Medicaid Services. Coverage is limited to routine services for Category A IDE studies and devices and related services for Category B IDE studies when not supplied by the trial sponsor. Approved IDE studies are posted on www.cms.gov/medicare/coverage/evidence.
Cimzia must not be used in combination with other biologic DMARDs, such as adalimumab (Humira, biosimilars) or etanercept (Enbrel), or with apremilast (Otezla) or tofacitinib (Xeljanz/XR), where prohibited by the applicable indication criteria.
Coverage is not available for investigational medical treatments or procedures, drugs, devices, or biological products. Use of Cimzia for indications or dosages other than those listed in this policy is considered investigational, as is use when patient-selection criteria are not met, except where specifically identified as not medically necessary.
Use of Cimzia is considered not medically necessary when the applicable disease-specific patient-selection criteria are not met, including the required treatment failures or restrictions for rheumatoid arthritis, psoriatic arthritis, active ankylosing spondylitis, moderate to severe plaque psoriasis, active non-radiographic axial spondyloarthritis, and polyarticular juvenile idiopathic arthritis.
For rheumatoid arthritis, psoriatic arthritis, and polyarticular juvenile idiopathic arthritis, the patient must have failed treatment with one or more traditional DMARDs, such as methotrexate, unless clinical evidence or patient history suggests those products will be ineffective or cause an adverse reaction.
For active ankylosing spondylitis, the patient must have failed treatment with NSAIDs unless clinical evidence or patient history suggests those products will be ineffective or cause an adverse reaction.
For moderate to severe plaque psoriasis, the patient must have greater than 10% of body surface area affected, or 10% or less with plaque psoriasis involving sensitive areas or areas that would significantly impact daily function, such as the palms, soles of the feet, head/neck, or genitalia.
For plaque psoriasis, the patient must have failed to respond to an adequate trial of UVB, PUVA, or systemic therapy such as methotrexate, cyclosporine, or acitretin.
For active non-radiographic axial spondyloarthritis, the patient must have failed at least TWO months of current continuous therapy with at least TWO different oral NSAIDs at prescription-strength dosages.
For polyarticular juvenile idiopathic arthritis, the patient must have failed treatment with one or more traditional DMARDs, such as methotrexate, unless clinical evidence or patient history suggests those products will be ineffective or cause an adverse reaction.
Continued use of Cimzia is considered not medically necessary when the patient has not experienced a beneficial clinical response from baseline before Cimzia.